Recent Finacing
Recent Raise
BioElectron develops redox therapeutics—EPI-743 (pre-NDA for inherited mitochondrial disease) and EPI-589 (for adult neurodegenerative diseases)—using an oxidoreductase-based discovery platform targeting CNS and systemic inflammatory pathologies.
